Bronchopulmonary dysplasia as a trial endpoint: time for re-evaluation?
- 1 October 2019
- journal article
- editorial
- Published by Elsevier BV in The Lancet Child & Adolescent Health
- Vol. 3 (12), 842-844
- https://doi.org/10.1016/s2352-4642(19)30321-9
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- The Diagnosis of Bronchopulmonary Dysplasia in Very Preterm Infants An Evidence-based ApproachAmerican Journal of Respiratory and Critical Care Medicine, 2019
- Changes in long-term prognosis with increasing postnatal survival and the occurrence of postnatal morbidities in extremely preterm infants offered intensive care: a prospective observational studyThe Lancet Child & Adolescent Health, 2018
- Bronchopulmonary dysplasia appropriateness as a surrogate marker for long-term pulmonary outcomes: A Systematic reviewJournal of Neonatal-Perinatal Medicine, 2018
- Bronchopulmonary Dysplasia: Executive Summary of a WorkshopThe Journal of Pediatrics, 2018
- Neonatal Caffeine Treatment and Respiratory Function at 11 Years in Children under 1,251 g at BirthAmerican Journal of Respiratory and Critical Care Medicine, 2017
- Revisiting the Definition of Bronchopulmonary DysplasiaJAMA Pediatrics, 2017
- Late Outcomes of a Randomized Trial of High-Frequency Oscillation in NeonatesThe New England Journal of Medicine, 2014
- Survival Without Disability to Age 5 Years After Neonatal Caffeine Therapy for Apnea of PrematurityJAMA, 2012
- Caffeine Therapy for Apnea of PrematurityNew England Journal of Medicine, 2006
- Validation of the National Institutes of Health Consensus Definition of Bronchopulmonary DysplasiaPediatrics, 2005